TicketManager Acquires Ovations, Expanding Leadership in Global Corporate Ticket Management

BUSINESS WIRE)--TicketManager, the world's leading provider of corporate ticket and guest management software, today announced the acquisition of substantially all of the assets of Ovations, a corporate ticketing solutions and hospitality platform serving Fortune 500 companies across key industries.
The acquisition adds top-tier enterprise customers to the growing TicketManager community and further strengthens the company's position as the global leader in corporate ticketing and event management solutions. Ovations' clients will now gain access to TicketManager's powerful technology, analytics, and expanded suite of integrations that make client entertainment simple, compliant, and measurable.
'Ovations is a trailblazer in our industry and we're excited to welcome the team, and their loyal customers, to the TicketManager community,' said Tony Knopp, CEO and Co-Founder of TicketManager. 'We've built the largest and most connected network of companies and teams that understand the power of client entertainment, and are focused on using it to drive real business results.'
For more than 20 years, Ovations has supported companies in managing their ticketing, hospitality, and sponsorship assets with an emphasis on compliance, approval workflows, and detailed reporting. Its client roster includes global financial institutions, top consumer brands, and major media organizations.
As part of the transition, members of the Ovations team have joined TicketManager's award-winning organization to ensure uninterrupted service and consistent support for clients. This acquisition reinforces TicketManager's dedication to helping companies provide seamless client experiences and maximize ROI from corporate entertainment and follows the 2021 acquisition of ticket and guest management firm Sports Systems.
'We're just getting started,' said Knopp. 'Stay tuned for some big news in the coming weeks as we work to make live events easy and prove the ROI for companies, and events, of all sizes.'
About TicketManager:
TicketManager is a leading event- and guest-management platform that empowers companies to make client entertainment easy and drive greater return on investment. It offers convenient and simple technology to manage corporate sports and entertainment tickets, create exceptional guest life-cycle experiences, and measure effectiveness.
TicketManager is trusted by more than 500 global brands including Verizon, FedEx, Adidas, Anheuser-Busch, and Mastercard. It is an official partner of numerous professional and collegiate sports organizations, including franchises in the National Football League, National Basketball Association, National Hockey League, Major League Baseball, Major League Soccer, and programs throughout the National Collegiate Athletics Association. For more information visit TicketManager.com.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

New York Post

7 hours ago

• New York Post

Weiner wars — Employee at popular meat company steals its secret recipe and then goes to work for competitor

So that's how the sausage is made. A former employee at Hormel Foods, a Fortune 500 packaged meat company, left with top-secret sausage recipes and market information — and then joined its regional competitor Johnsonville, a new federal lawsuit alleges. The stew started after longtime Hormel employee Brett Sims landed the role of Johnsonville's chief supply chain officer in June 2023, and then allegedly began poaching Hormel employees to also join the staff at the sausage company, based in Sheboygan Falls, Wisconsin, which was in violation of his non-solicitation agreement. Sims brought in his former Hormel co-worker Jeremy Rummel this spring, who left Hormel after 25 years, as per The Star Tribune. Before he broke the news to Hormel that he was about to work for its competitor, Rummel allegedly sent 'product formulas, processing procedures, acquisition-target information and marketing-strategy information' to his personal email address. Hormel Foods was founded 130 years ago. Getty Images 'Rummel was attempting to take Hormel's confidential business information and trade secrets to Johnsonville for the express purpose of exploiting the information for Johnsonville's benefit and to Hormel's detriment,' the suit said. After Hormel confronted Rummel, he fessed up to emailing himself the confidential information and then promptly headed to Sims' house 'with the intent to share the details of his interview with Hormel and develop a plan to protect his new role at Johnsonville,' according to the lawsuit. Hormel is behind brands like Spam, Skippy and Planters. SOPA Images/LightRocket via Getty Images Hormel, which was founded 130 years ago and is also behind brands like Skippy, Spam and Planters, is accusing Johnsonville and the two ex-employees of conspiring to 'unlawfully obtain Hormel's trade secrets.' 'The sausage market is increasingly competitive, and improper use of confidential, proprietary and trade-secret information, or wrongful competition or solicitation, could cause a manufacturer significant competitive economic disadvantage,' the suit continued. To make matters worse, when Johnsonville was sent a letter from Hormel 'outlining Sims' and Rummel's violations of their agreements, detailing their unlawful behavior and asking for a number of assurances,' the company did not cooperate, the suit claims. Sims and Rummel did not immediately respond to the Star Tribune's email, nor did an attorney named in the lawsuit.

Business Wire

12 hours ago

• Business Wire

GE HealthCare drives innovation in theranostics with latest technological advances

CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processing i – an AI-powered innovation to help aid physician decision making and therapy response monitoring. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief Share With cancer accounting for over 10 million deaths globally each year, ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing, i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. 'At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.' Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni, iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40% iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities vi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systems vii – with the ability to reduce the dose up to 82%, viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. 'Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,' says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other region. ii Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, 2023. iii Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. iv Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing. v Based on orders data of GE HealthCare PET/CT systems since 2010. vi Compared to NM/CT 870 DR. vii As compared to NM/CT 870 DR with Optima 540 CT. viii a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability). viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.

Business Insider

16 hours ago

• Business Insider

Meet the Gen Z HENRYs: They're making $565K on average but still renting

Earning six figures but living paycheck to paycheck — that's what it means to be a HENRY. As Gen Zers approach 30, a very small subset of the generation is aging into this acronym, which stands for high earners, not rich yet, and was coined by Fortune's Shawn Tully. With inflation biting extra hard during their young adult years, younger Americans increasingly think they need to earn more to achieve stability. In a 2024 Bankrate survey, Gen Zers said they'd need to make $200,000 a year to feel financially secure. At the same time, Gen Zers deal with " money dysmorphia," or an unrealistic perception of their own financial soundness and feeling stressed over money, largely due to social comparison and outdated ideas of what's affordable. Indeed, middle-income Americans have been living more like their lower-income counterparts, indicating that for Americans to feel middle-class, they actually need to be high-earning. To figure out who in Gen Z is actually earning above that threshold — and may exemplify the HENRY title — we delved into Census Bureau microdata from the Current Population Survey's 2024 Annual Social and Economic Supplement. We only looked at adult Gen Zers with a total income of $250,000 or more. Though Gen Z birth years span from 1997 to 2012, we only looked at those ages 18 to 27 in 2024. On average, these Gen Z HENRYs made just above $565,000 a year, compared to around $28,700 for all Gen Zers reflected in the microdata. They also skewed slightly more male than the wider Gen Z cohort. On average, Gen Z HENRYs were around 24 years old in 2024. They were also more likely to be married than their wider Gen Z cohort, and those marriages seem to be sticking so far — essentially 0% of Gen Z HENRYs were separated or divorced. Demographically, Gen Z HENRYs were also less likely to be white than their cohort peers, and more likely to be Asian or Pacific Islander. Gen Z HENRYs were also more likely to have a bachelor's degree or a master's degree and beyond, both of which can contribute to a wage premium. And HENRYs might have the entrepreneurial bug: They're more likely than the rest of Gen Z to be self-employed, although the vast majority held wage or salary roles in the private sector. Gen Z HENRYs were less likely to be homeowners than the wider Gen Z cohort, with 40% of HENRYs owning homes compared to around 53% of all Gen Zers. Conversely, HENRYs were more likely to be renters. However, homeowning HENRYs were more likely to live in more valuable properties — their estimated current property values were around $455,000 compared to around $441,000 for all of Gen Z. That tracks with a larger trend: Some high-earning Americans, especially younger ones, are opting for rent — it's increasingly become a better deal than maintaining and buying a home for many, and many higher-earners like the flexibility and amenities that come with a rental.